Pepducin Inhibition of Protease-activated Receptor 2 Attenuates a Mouse Model of Abdominal Aortic Aneurysm

被引：0
|
作者：
Russell, Hannah M.
Conrad, Kelsey A.
Benoit, Joshua A.
Wanhainen, Anders
Mix, Doran S.
Cameron, Scott J.
Covic, Lidija
Kuliopulos, Athan
Owens, A. Phillip, III
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A449
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pepducin - A Novel Protease-Activated Receptor-2 (par2) Inhibitor - Attenuates Experimental Pulmonary Hypertension
    Warburton, R.
    Kuliopulos, A.
    Wieschhaus, A.
    Kayyali, U. S.
    Toksoz, D.
    Fanburg, B. L.
    Preston, I. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [2] Protease-Activated Receptor 4 Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm and Rupture
    Owens, A. Phillip, III
    Rateri, Debra L.
    Howatt, Deborah A.
    Steinhubl, Steven R.
    Daugherty, Alan
    Mackman, Nigel
    CIRCULATION, 2011, 124 (21)
  • [3] Deficiency of Protease-activated Receptor 2 Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm Independent of Vascular Smooth Muscle Cell Tissue Factor
    Hall, David E.
    Mann, Adrien
    Jones, Shannon M.
    Mackman, Nigel
    Owensiii, Phillip
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36
  • [4] A humanized protease-activated receptor-2 mouse as a model for allergic asthma
    Gillman, Samuel
    Schiff, Hillary
    Pederson, Wil
    Sandoval, Estevan
    Rivera, Benjamin
    Dussor, Gregory
    Price, Theodore
    Vagner, Josef
    Defea, Kathryn
    Boitano, Scott
    PHYSIOLOGY, 2023, 38
  • [5] Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin
    Shearer, Andrew M.
    Rana, Rajashree
    Austin, Karyn
    Baleja, James D.
    Nguyen, Nga
    Bohm, Andrew
    Covic, Lidija
    Kuliopulos, Athan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (44) : 23188 - 23198
  • [6] Drug repositioning as an effective therapy for protease-activated receptor 2 inhibition
    Saqib, Uzma
    Savai, Rajkumar
    Liu, DongFang
    Banerjee, Sreeparna
    Baig, Mirza S.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (02) : 1522 - 1526
  • [7] Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach
    Covic, Lidija
    Kuliopulos, Athan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [8] PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice
    Jones, Shannon M.
    Mann, Adrien
    Conrad, Kelsey
    Saum, Keith
    Hall, David E.
    McKinney, Lisa M.
    Robbins, Nathan
    Thompson, Joel
    Peairs, Abigail D.
    Camerer, Eric
    Rayner, Katey J.
    Tranter, Michael
    Mackman, Nigel
    Owens, A. Phillip, III
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (06) : 1271 - 1282
  • [9] INHIBITION OF CATHEPSIN S AND PROTEASE-ACTIVATED RECEPTOR-2 DEFICIENCY REDUCE ALLOGRAFT VASCULOPATHY IN A HETEROTOPIC MURINE AORTIC TRANSPLANTATION MODEL
    Ryll, M.
    Lei, Y.
    Thomas, M. N.
    Li, M.
    Kripp, H.
    Bazhin, A.
    Werner, J. M.
    Anders, H. -J.
    Andrassy, J.
    TRANSPLANT INTERNATIONAL, 2021, 34 : 12 - 13
  • [10] Roles of protease-activated receptors in a mouse model of endotoxemia
    Camerer, Eric
    Cornelissen, Ivo
    Kataoka, Hiroshi
    Duong, Daniel N.
    Zheng, Yao-Wu
    Coughlin, Shaun R.
    BLOOD, 2006, 107 (10) : 3912 - 3921
12345